{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Katie", "organization": "", "rank": 1, "lastname": "THOMAS"}], "original": "By KATIE THOMAS"}, "news_desk": "Business", "slideshow_credits": null, "abstract": null, "multimedia": [{"type": "image", "url": "images/2016/11/05/business/05ADRENACLICKweb1/05ADRENACLICKweb1-thumbWide.jpg", "legacy": {"wide": "images/2016/11/05/business/05ADRENACLICKweb1/05ADRENACLICKweb1-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/11/05/business/05ADRENACLICKweb1/05ADRENACLICKweb1-articleLarge.jpg", "legacy": {"xlarge": "images/2016/11/05/business/05ADRENACLICKweb1/05ADRENACLICKweb1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "899"}, "width": 600, "subtype": "xlarge", "height": 899}, {"type": "image", "url": "images/2016/11/05/business/05ADRENACLICKweb1/05ADRENACLICKweb1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/11/05/business/05ADRENACLICKweb1/05ADRENACLICKweb1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"print_headline": "A Promising Rival to EpiPen Fails to Gain Traction", "main": "Why the Lone EpiPen Competitor Hasn\u2019t Taken Off"}, "print_page": "1", "keywords": [{"value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Generic Brands and Products", "is_major": "N", "rank": "5", "name": "subject"}, {"value": "Medical Devices", "is_major": "N", "rank": "6", "name": "subject"}, {"value": "Epinephrine (Drug)", "is_major": "N", "rank": "7", "name": "subject"}, {"value": "Mylan Inc", "is_major": "N", "rank": "8", "name": "organizations"}, {"value": "Impax Laboratories Inc", "is_major": "N", "rank": "9", "name": "organizations"}], "snippet": "Adrenaclick, a cheaper alternative, has benefited from furor over EpiPen pricing. But its maker is struggling to meet demand, and a generic EpiPen is near....", "source": "The New York Times", "lead_paragraph": "Adrenaclick, a cheaper alternative, has benefited from furor over EpiPen pricing. But its maker is struggling to meet demand, and a generic EpiPen is near.", "word_count": "1240", "pub_date": "2016-11-01T09:00:19Z", "subsection_name": null, "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/11/02/business/also-ran-to-epipen-reaches-for-a-closing-window-of-opportunity.html", "_id": "581859ab7c459f606398cde8"}